Pfizer considers nixing $160B Allergan merger amidst new tax regulations — 3 insights

New York City-based Pfizer, a pharmaceutical company, is questioning whether it should move forward with its Dublin, Ireland-based Allergan merger after the Obama administration implemented new rules on tax inversion, according to The Hill.

Here are three insights:

1. The merger between the two drug companies is valued at $160 billion and is the largest of its kind to date.

2. The Treasury Department implemented strict new rules on tax inversions, which many view as a way to block the Pfizer-Allergan merger.

3. Pfizer opted to move its tax addresses to Dublin to save billions in tax revenues, resulting in political scrutiny from candidates including Hillary Clinton and Donald Trump.  

More articles on quality & infection control:
Consumers don't link prices with quality — 4 key points
Should medical professionals use body cameras? 4 notes
Quality problems surround Theranos' medical testing — 5 observations

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers

Featured Podcast